Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue and subsequently identified as a key modulator of innate and adaptive immune signalling. First characterised by Allan Goldstein and colleagues at the George Washington University in 1977, Tα1 is encoded endogenously by the PTMA gene and processed from the precursor protein prothymosin alpha. Across several decades of preclinical and clinical research, it has been one of the most extensively studied immunomodulatory peptides, with particular interest in T-cell biology, toll-like receptor signalling, and viral immune response models. Researchers looking to source Thymosin Alpha-1 for laboratory use can view our Thymosin Alpha-1 10mg Research Pen or browse the full research compound catalogue.
Important Distinction: Thymosin Alpha-1 vs Thymosin Beta-4 (TB-500)
Thymosin Alpha-1 and Thymosin Beta-4 are frequently confused due to shared nomenclature, but they are structurally distinct peptides with entirely different mechanisms of action and research applications. The two compounds share no sequence homology and operate through separate biological pathways.
- Thymosin Alpha-1 (Tα1): 28 amino acids; derived from the PTMA gene; primary activity in immune cell modulation — specifically T-cell maturation, dendritic cell function, and toll-like receptor signalling
- Thymosin Beta-4 (TB-500): 43 amino acids; derived from the TMSB4X gene; primary activity in actin dynamics, cell migration, angiogenesis, and connective tissue repair models
The shared “Thymosin” designation reflects their common origin of discovery — both were isolated from thymic tissue extracts — but they are biologically and mechanistically unrelated. For detailed coverage of Thymosin Beta-4’s mechanisms, see our guide: TB-500 (Thymosin Beta-4): Mechanism of Action and Current Research Landscape.
Molecular Structure and Properties
Thymosin Alpha-1 is a 28-amino acid peptide with the sequence:
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
The N-terminus is acetylated, a post-translational modification present in the endogenous form and reproduced in synthetic analogues. This acetylation is considered important for biological activity and stability.
Key physicochemical properties:
- Molecular formula: C₁₂₉H₂₁₅N₃₃O₅₅
- Molecular weight: 3,108 Da
- Sequence length: 28 amino acids
- N-terminal modification: Acetylated (Ac-Ser)
- CAS number: 62304-98-7
- Supplied as: lyophilised powder for in vitro research use
Primary Mechanism: T-Cell Modulation and Thymic Biology
Thymosin Alpha-1’s best-characterised function involves the maturation and differentiation of T-lymphocytes (T-cells) within the thymic microenvironment. The thymus produces endogenous Tα1 as part of the normal process by which immature thymocytes develop into functional T-cells capable of antigen recognition and immune coordination.
In vitro and preclinical research has identified several mechanisms through which Tα1 exerts its immunomodulatory effects:
- Thymocyte maturation: Tα1 promotes the differentiation of immature CD4−CD8− thymocytes into mature CD4+ and CD8+ T-cell populations, facilitating the generation of functionally competent lymphocytes
- T-helper cell polarisation: Research in murine models has shown Tα1 promotes Th1 cytokine profiles (IFN-γ, IL-2) over Th2 responses, a pattern relevant to models examining antiviral and antifungal immune activity
- Regulatory T-cell modulation: Evidence suggests Tα1 can influence T-regulatory (Treg) cell populations, with proposed implications for immune tolerance research
Toll-Like Receptor Signalling and Innate Immunity
Beyond its role in adaptive T-cell biology, Tα1 has been shown to act as an agonist at toll-like receptors (TLRs) — specifically TLR2 and TLR9 — which are pattern recognition receptors central to innate immune detection of microbial pathogens.
A key study by Romani et al. (2007, Journal of Experimental Medicine) characterised the TLR9 agonist activity of Tα1 in dendritic cells, demonstrating that Tα1 stimulated TLR9-mediated signalling cascades, induced IDO (indoleamine 2,3-dioxygenase) expression, and promoted a tolerogenic dendritic cell phenotype. This work identified a mechanistic basis for Tα1’s observed dual capacity to enhance antigen-specific immune responses while simultaneously modulating immune tolerance.
Research by Garaci et al. (2009) further characterised Tα1’s interaction with dendritic cell subsets, showing that plasmacytoid dendritic cells (pDCs) — key producers of type I interferons — respond to Tα1 stimulation with enhanced IFN-α production, providing a mechanistic link to its activity in viral immune response models.
Dendritic Cell Biology and Antigen Presentation
A significant body of preclinical research has focused on Tα1’s effects on dendritic cells (DCs), the primary antigen-presenting cells that bridge innate and adaptive immunity. Key observations from in vitro studies include:
- Promotion of DC maturation and upregulation of MHC class II and co-stimulatory molecules (CD80, CD86)
- Enhanced antigen processing and presentation capacity in treated DC cultures
- Modulation of cytokine secretion profiles — particularly increased IL-12 production, which supports Th1 polarisation of naïve T-cells
- IDO induction in specific DC subsets, linking Tα1 to tryptophan metabolism and immune regulatory networks
Research Applications
Viral Immune Response Models
Thymosin Alpha-1 has been studied extensively in the context of viral immune challenge models. Preclinical and some clinical research has examined its role in augmenting antigen-specific immune responses in settings where T-cell function may be compromised or insufficient. Research published in journals including Clinical and Experimental Immunology and International Immunopharmacology has documented Tα1-associated changes in T-cell counts, cytokine profiles, and NK cell activity in various experimental contexts.
A notable area of published research concerned Tα1 in the context of hepatitis B and C viral models. Clinical trial data published over several decades — including work by Andreone et al. (1996) and subsequent investigators — examined virological and immunological parameters in study populations receiving Tα1. These studies represent published clinical data but should be evaluated critically in the context of their design and endpoints. All such research is referenced here in its scientific context only.
Immune Senescence Research
Age-associated decline in thymic function (thymic involution) reduces endogenous Tα1 production and is associated with impaired T-cell output and immune senescence. Research models have examined whether exogenous Tα1 can partially restore aspects of thymic-dependent immune function in aged animal models, making it a compound of interest in longevity and immune biology research. For context on related longevity research, our guide on Epithalon: Structure, Synthesis and Research covers another peptide studied in the neuroendocrine and ageing research context.
Fungal Infection Models
Research by Romani and colleagues examined Tα1 in Aspergillus fumigatus infection models in murine systems, reporting that Tα1 treatment was associated with enhanced neutrophil and DC responses to fungal challenge. Published findings demonstrated improved survival in challenged immunocompromised mice in preclinical settings — data referenced here solely as published scientific findings, not as evidence of therapeutic application.
Cancer Immunology Models
Preclinical research has examined Tα1 in the context of tumour immunology, with particular interest in its capacity to restore T-cell function in immunosuppressed animal models and to potentiate responses to other immune stimuli. Some studies have examined Tα1 in combination with other agents in preclinical oncology models. This remains an active area of preclinical investigation.
Research Status and Literature
Thymosin Alpha-1 has one of the more extensive peer-reviewed literature bases among research peptides:
- Zadaxin (thymalfasin), the pharmaceutical-grade form of Tα1, has received regulatory approval in several Asian and Eastern European countries for specific clinical indications — distinct from research-grade compounds supplied for in vitro use
- Multiple Phase II and Phase III clinical trials have been conducted and published, primarily in hepatitis B, hepatitis C, and immune reconstitution research contexts — all referenced here as published scientific literature
- Preclinical literature spans T-cell biology, dendritic cell biology, antifungal immune models, antiviral immune models, and oncology immunology
- The compound’s endogenous origin and established safety profile in clinical research settings have made it a well-characterised tool for immune biology research
Research-grade Thymosin Alpha-1 for in vitro use is distinct from any licensed pharmaceutical formulation. It is not approved for human administration in this context and is supplied exclusively for laboratory research purposes.
Thymosin Alpha-1 vs TB-500: A Quick Reference
For researchers working across immunology and tissue repair models, the following comparison summarises the key distinctions between these two thymosins:
- Origin: Both derived from thymic tissue extracts; no further structural relationship
- Size: Tα1 = 28 amino acids; TB-500 (Tβ4) = 43 amino acids
- Gene: Tα1 from PTMA; TB-500 from TMSB4X
- Primary mechanism: Tα1 acts on TLR signalling, T-cell maturation, dendritic cell biology; TB-500 acts on G-actin sequestration, VEGF/ILK/AKT signalling, NF-κB modulation
- Research applications: Tα1 — immune biology, viral/fungal response models, immune senescence; TB-500 — tissue repair, connective tissue, angiogenesis, cardiac models
- Literature base: Tα1 has clinical trial data; TB-500 literature is primarily preclinical
Sourcing Thymosin Alpha-1 for In Vitro Research
R&D Peptides supplies Thymosin Alpha-1 10mg, lyophilised and accompanied by a batch-specific Certificate of Analysis confirming purity by HPLC and molecular weight by mass spectrometry. Supplied strictly for in vitro research use only.
For quality and testing standards, see our quality and testing page, or review our guidance on interpreting Certificates of Analysis for peptide research.
Key Takeaways
- Thymosin Alpha-1 is a 28-amino acid acetylated peptide derived from the PTMA gene, with endogenous roles in thymic T-cell maturation and immune modulation.
- It is mechanistically and structurally distinct from Thymosin Beta-4 (TB-500) — the shared “Thymosin” name reflects common discovery origin only.
- Primary mechanisms include TLR2/TLR9 agonism, T-cell and thymocyte maturation signalling, dendritic cell activation, and Th1 cytokine polarisation.
- Research applications span viral immune response models, fungal infection models, immune senescence, and cancer immunology.
- It has one of the most extensive clinical research literatures among peptide research compounds, including published Phase II/III trial data — all referenced in scientific context only.
- Research-grade Tα1 is supplied for in vitro laboratory use and is not intended for human administration.
Frequently Asked Questions
Is Thymosin Alpha-1 the same as TB-500?
No. Thymosin Alpha-1 and TB-500 (Thymosin Beta-4) are entirely distinct peptides sharing only a historical naming convention from their co-discovery in thymic extracts. They differ in amino acid sequence, gene origin, molecular weight, mechanism of action, and research application. Tα1 is an immune modulator; TB-500 is an actin-binding peptide with roles in tissue repair and angiogenesis research models. For a full mechanistic overview of TB-500, see our TB-500 research guide.
What is the molecular weight of Thymosin Alpha-1?
Thymosin Alpha-1 has a molecular weight of approximately 3,108 Da. It is a 28-amino acid peptide with an acetylated N-terminus (Ac-Ser), molecular formula C₁₂₉H₂₁₅N₃₃O₅₅, and CAS number 62304-98-7.
What is the difference between research-grade Thymosin Alpha-1 and Zadaxin?
Zadaxin (thymalfasin) is a pharmaceutical-grade formulation of synthetic Tα1 approved for specific clinical indications in a number of countries. Research-grade Thymosin Alpha-1 as supplied by R&D Peptides is produced for in vitro laboratory research use only. It is not a pharmaceutical product, is not approved for human administration, and no therapeutic claims are made or implied.
How should Thymosin Alpha-1 be stored for research use?
Lyophilised Thymosin Alpha-1 should be stored at −20°C in a sealed, desiccated container protected from light and moisture. Once reconstituted, research solutions should be aliquoted into single-use volumes and stored at −80°C where long-term stability is required. For general guidance on peptide reconstitution and storage best practices, visit our research hub.
Where can researchers source Thymosin Alpha-1?
R&D Peptides supplies Thymosin Alpha-1 10mg as a research-grade compound verified by HPLC at ≥98% purity, accompanied by a Certificate of Analysis. Browse our full range of research compounds or the complete product catalogue. All compounds are for laboratory research use only and are not intended for human consumption.
All content on this page is for educational and informational purposes only. Thymosin Alpha-1 is supplied by R&D Peptides strictly for in vitro research use. It is not intended for human or veterinary administration, and no therapeutic claims are made or implied.
